Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia

Journal of the National Medical Association

Volumn 99, Issue 1, 2007, Pages 57-63

  Beyazit, Yavuz ^a   Aksu, Salih ^a   Haznedaroglu, Ibrahim C ^a   Kekilli, Murat ^a   Misirlioglu, Muge ^a   Tuncer, Serdar ^a   Karakaya, Jale ^a,b   Koca, Ebru ^a   Buyukasik, Yahya ^a   Sayinalp, Nilgun ^a   Goker, Hakan ^a   Ozcebe, Osman I ^a  

^a Department of Internal Medicine ^*  (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Angiotensin converting enzyme; Myeloid leukemia; Renin angiotensin system; Reverse transcription polymerase chain reaction

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; RENIN; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; BONE MARROW BIOPSY; BONE MARROW CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; LEUKEMOGENESIS; MALE; MICROENVIRONMENT; PARACRINE SIGNALING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RNA ISOLATION; UMBILICAL CORD BLOOD;

ACUTE DISEASE; ANGIOTENSINS; BONE MARROW; GENE EXPRESSION REGULATION, LEUKEMIC; LEUKEMIA, MYELOID; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33846590649     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Montgomery H, Humphries SE, Leung PS. Renin-angiotensin Systems: the new frontier. Int J Biochem Cell Biol. 2003;35:758.
2. Haznedaroglu IC, Ozturk MA. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol. 2003;35:867-880.
3. Haznedaroglu IC, Tuncer S, Gursoy M. A local renin-angiotensin system in the bone marrow. Med Hypotheses. 1996;46:507-510.
4. Haznedaroglu IC. A local renin-angiotensin system in the bone marrow still awaits its Christopher Columbus. Exp Hematol. 1998;26:279.
5. Boranic M. While waiting for Christopher Columbus to discover alternative route(s) of bone marrow regulation, keep faith the body is a global system. Exp Hematol. 1998;26:1018-1019.
6. Vasku A, Holla L, Znojil V. The best model of a cat is a cat, especially the same cat. Exp Hematol. 1999;27:187-188.
7. Haznedaroglu IC. A local renin-angiotensin system in the bone marrow: hypothesis and clues. Exp Hematol. 1999;27:186-187.
8. Strawn WB, Richmond RS, Ann TE, et al. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol. 2004;126:120-126.
9. Rodgers KE, Xiong S, Steer R, et al. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287-294.
10. Haznedaroglu IC, Ozturk MA. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol. 2003;35:867-880.
11. Brunet dlG, Ivanovic Z, Leprivey-Lorgeot V, et al. Angiotensin II that reduces the colony-forming ability of hematopoietic progenitors in serum free medium has an inverse effect in serum-supplemented medium. Stem Cells. 2002;20:269-271.
12. Peng C, Li WM, Ma YP, et al. [Effect of angiotensin II on cord blood CD34(+) cells expansion in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11:227-229.
13. Goker H, Haznedaroglu IC, Beyazit Y, et al. Local umbilical cord blood renin-angiotensin system. Ann Hematol. 2005;84:277-281.
14. Richmond RS, Tallant EA, Gallagher PE, et al. Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. J Renin Angiotensin Aldosterone Syst. 2004;5:176-182.
15. Abali H, Haznedaroglu IC, Goker H, et al. Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology. 2002;7:75-82.
16. Wulf GG, Jahns-Streubel G, Nobiling R, et al. Renin in acute myeloid leukaemia blasts. Br J Haematol. 1998;100:335-337.
17. Wulf GG, Jahns-Streubel G, Strutz F, et al. Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol. 1996;73:139-141.
18. Teresa Gomez Casares M, de la Iglesia S, Perera M, et al. Renin expression in hematological malignancies and its role in the regulation of hematopoiesis. Leuk Lymphoma. 2002;43:2377-2381.
19. Pinto RP, Wang KK, Khoury H, et al. Aberrant expression of angiotensin in acute myeloid leukemia. Blood. 2003;102:2124A.
20. Abali H, Gullu IH, Engin H, et al. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses. 2002;59:344-348.
21. Ozturk MA, Guven GS, Haznedaroglu IC. How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems. Med Hypotheses. 2004;63:866-874.
22. Goulter AB, Goddard MJ, Allen JC, et al. ACE2 gene expression is upregulated in the human failing heart. BMC Med. 2004;2:19.
23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
24. Marusic-Vrsalovic M, Dominis M, Jaksic B, et al. Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol. 2003;123:539-541.
25. Danilov SM, Sadovnikova E, Scharenborg N, et al. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol. 2003;31:1301-1309.
26. Hajek D, Tomiska M, Krahulcova E, et al. I/D ACE gene polymorphism in survival of leukemia patients-hypothesis and pilot study. Med Hypotheses. 2003;61:80-85.
27. Rodgers KE, Xiong S, Steer R, et al. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287-294.
28. Haznedaroglu I, Tokgozoglu L, Caglar M, et al. Local cardiac renin-angiotensin system and hypertensive heart disease. Hypertension. 1994;24:816-818.
29. Haznedaroglu IC. Angiotensin I-converting enzyme, blood groups, and a local marrow-specific renin-angiotensin system. Exp Hematol. 1997;25:93.
30. Cobankara V, Ozturk MA, Kiraz S, et al. Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis. Rheumatol Int. 2005;25:285-291.
31. Nobuhiko A, Suganuma E, Babaev VR, et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2143-2148.
32. Ishibashi M, Egashira K, Zhao Q, et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004;24:e174-178.
33. Charrier S, Michaud A, Badaoui S, et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004;104:978-985.
34. Haznedaroglu IC, Arici M, Buyukasik Y. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses. 2000;54:80-83.
35. Rodgers KE, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol. 2002;49:403-411.
36. Ellefson DD, diZerega GS, Espinoza T, et al. Synergistic effects of coadministration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol. 2004;53:15-24.
37. Haznedaroglu IC. Postrenal transplant erythrocytosis, ACE inhibitors and a hypothetical local renin-angiotensin system in the bone marrow. Clin Nephrol. 1997;48:60.
38. Haznedaroglu IC, Buyukasik Y. Current evidence for the existence of a local renin-angiotensin system affecting physiological and pathological haemopoiesis in the bone marrow. Br J Haematol. 1997;99:471.
39. Leung PS. The peptide hormone angiotensin II: its new functions in tissues and organs. Curr Protein Pept Sci. 2004;5:267-273.
40. Defard M, Lemoine FM, Bonnet ML, et al. Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. Leuk Lymphoma. 1997;27:487-494.
41. Wdzieczak-Bakala J, Grillon C, Robinson S, et al. Catabolism of the tetrapeptide N-Ac-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of hematopoietic stem cell (CFU-S) proliferation, following in vitro incubation with hematopoietic tissues from normal and leukemic mice. Bull Cancer. 1993;80:391-396.
42. Comte L, Lorgeot V, Bignon J, et al. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide. Eur J Clin Invest. 1998;28:856-863.
43. Chisi JE, Briscoe CV, Ezan E, et al. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol. 2000;109:563-570.
44. Chisi JE, Wdzieczak-Bakala J, Thierry J, et al. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells. 1999;17:339-344.
45. Wierenga PK, Konings AW. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage. Exp Hematol. 1996;24:246-252.
46. Wierenga PK, Konings AW. Seraspenide (AcSDKP) mediated protection of hematopoietic stem cells in a hyperthermic purging protocol. Prog Clin Biol Res. 1994;389:189-195.
47. Najman A, Bonnet D, Isnard F, et al. [Effects of the tetrapeptide AcSDKP on normal and leukemic bone marrow]. Nouv Rev Fr Hematol. 1993;35:279-280.
48. Liozon E, Pradelles P, Venot J, et al. Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 1993;7:808-812.
49. Bonnet D, Cesaire R, Lemoine F, et al. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. Exp Hematol. 1992;20:251-255.
50. Wierenga PK, Setroikromo R, Vellenga E, et al. Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophos-pholipid ET-18-OCH(3). Br J Haematol. 2000;111:1145-1152.
51. Liozon E, Volkov L, Comte L et al. AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemia. Br J Haematol. 1995;89:917-920.
52. Caires AC, Oliveira CR, Smith MC, et al. Effects of palladacycle complex on hematopoietic progenitor cells proliferation in vivo and in vitro and its relation with the inhibitory properties of this compound on the angiotensin-l converting enzyme activity. Immunopharmacol Immunotoxicol. 2004;26:487-500.